PTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed Friedreich's Ataxia Study
Portfolio Pulse from Vandana Singh
PTC Therapeutics' stock tumbles after the company reported that its MOVE-FA trial of vatiquinone in Friedreich ataxia patients failed to meet its primary endpoint. The company also discontinued preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization.
May 24, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics' stock price is likely to be negatively impacted by the failed MOVE-FA trial and discontinuation of preclinical gene therapy programs.
The failed MOVE-FA trial and discontinuation of preclinical gene therapy programs indicate setbacks in PTC Therapeutics' product pipeline, which may lead to a decrease in investor confidence and a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100